PTLF (Petlife Pharmaceuticals) Total Liabilities: $1.98 Mil (As of Feb. 2018)


What is Petlife Pharmaceuticals Total Liabilities?

Petlife Pharmaceuticals PTLF Total Liabilities is $1.98 Mil as of Feb. 2018.

Petlife Pharmaceuticals's Total Liabilities for the quarter that ended in Feb. 2018 was $1.98 Mil.

Petlife Pharmaceuticals's quarterly Total Liabilities increased from Aug. 2017 ($1.44 Mil) to Nov. 2017 ($1.83 Mil) and increased from Nov. 2017 ($1.83 Mil) to Feb. 2018 ($1.98 Mil).

Petlife Pharmaceuticals's annual Total Liabilities increased from Aug. 2015 ($0.37 Mil) to Aug. 2016 ($3.24 Mil) but then declined from Aug. 2016 ($3.24 Mil) to Aug. 2017 ($1.44 Mil).

Petlife Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals Total Liabilities Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.37 3.24 1.44

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 1.59 1.44 1.83 1.98

Petlife Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Petlife Pharmaceuticals's Total Liabilities for the fiscal year that ended in Aug. 2017 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.436+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.44

Total Liabilities=Total Assets (A: Aug. 2017 )-Total Equity (A: Aug. 2017 )
=0.055--1.381
=1.44

Petlife Pharmaceuticals's Total Liabilities for the quarter that ended in Feb. 2018 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.981+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.98

Total Liabilities=Total Assets (Q: Feb. 2018 )-Total Equity (Q: Feb. 2018 )
=0.008--1.973
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.98 Mil mean?
Petlife Pharmaceuticals (PTLF) has a Total Liabilities of $1.98 Mil as of Feb. 2018. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' Total Liabilities too high?
Petlife Pharmaceuticals' current Total Liabilities is $1.98 Mil.
How does Petlife Pharmaceuticals' Total Liabilities compare to PCYN and YBAO?
Petlife Pharmaceuticals' Total Liabilities of $1.98 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Petlife Pharmaceuticals and its competitors. Petlife Pharmaceuticals's current Total Liabilities is $1.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current Total Liabilities of $1.98 Mil. The current Total Liabilities is $1.98 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current Total Liabilities is $1.98 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.